Aim: To investigate the upstream therapeutic effects of fluvastatin and valsartan on hypertensive patients with non-permanent atrial fibrillation (AF).
D was significantly reduced after treatment (P < 0.01). There was no significant difference of hs-CRP level in group A (P > 0.05). The left ventricular remodeling was significantly alleviated in group C and group D (P < 0.05). The NT-ProBNP level was significantly decreased in group D (P < 0.05). (c) The sinus rhythm maintenance rate of group B, group C, and group D was higher than group A (77.78%, 70.45%, 79.17% vs 43.90%), the occurrence of persistent AF was significantly lower than group A (11.11%, 14.29%, 8.33% vs 31.71%; P < 0.05).
Conclusions: CCB plus fluvastatin and valsartan can reduce the recurrence rate of non-permanent AF and to delay the progression from non-permanent AF to permanent AF in patients with hypertension. The combined application of valsartan and fluvastatin is more effective than valsartan or CCB alone in the upstream therapies of AF.
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| INTRODUC TI ON
Atrial fibrillation (AF) is a frequent clinically cardiac arrhythmia with a high symptom burden compromising daily life and associated with increased mortality and morbidity. 1, 2 Several clinical risk factors for AF include age, valvular heart disease, obesity, heart failure, and hypertension. Of all the risk factors, hypertension is the most commonly encountered condition in patients with incident AF. 3 Although much effort has been put into anti-arrhythmic drugs and ablative therapies reduce the burden and improve symptoms of AF, no cure exists. This has led many to search for upstream or preventative therapies to delay the onset of AF. 4 Atrial fibrillation and concurrent cardiac disorders include atrial structural and electrical remodeling, which may further promote AF. 5 Since hypertension leads to electrical and structural alterations of the left atrium, hypertension is a key contributor to the substrate vulnerable to AF. In addition, dyslipidemia may be associated with an increased risk of AF, 6 anti-hypertensive and lipid-lowering therapies may reduce atrial remodeling and serve as potential upstream therapies for AF.
| ME THODS

| Study design and patient entry criteria
The study was registered with the Chinese Clinical Trial Registry ticipating medical centers, which are secondary or tertiary healthcare providers in China, and they all provided the proof of laboratory quality control. Written informed consent was obtained from all patients prior to the study. According to the experimental design scheme we designed previously, 7 the study was designed as a prospective, randomized, open-label, four-arm parallel, and multicenter study. The aim of the study was to explore whether the upstream therapy using valsartan or fluvastatin is more effective in reducing the recurrence of AF and the progress from non-permanent AF to permanent AF in hypertensive patients with non-permanent AF, compared with conventional anti-hypertensive therapy using dihydropyridine calcium channel blockers (CCBs).
The inclusion criteria were as follows: (a) hypertension, defined as an average systolic blood pressure ≥140 mm Hg and (o) pregnancy or the possibility of pregnancy, or breast feeding.
| Objective and group assignment
The present study was conducted from be recorded (including drug type, daily dose, starting and cessation date). The four groups were followed up for 24 months.
| Blood sample collection and measurement
Venous blood samples (10 mL) were obtained from patients in four groups to evaluate the routine blood test and blood biochemical examination. Specimens were drawn from the femoral vein using a 21-gauge needle. The specimens were transferred (by using vacuum pressure) as quickly as possible into tubes containing ethylenediaminetetraacetic acid (EDTA)-K2 (Beijing INSEPACK Co, China) anticoagulant after removal of syringe needles. Care was taken to ensure that the tubes were filled with the appropriate volume of blood and that the blood was mixed gently with the anticoagulant by inversion immediately after collection.
| Echocardiography examination
Cardiac function was evaluated using a commercially available ultrasound system with IE 33 (Philips Healthcare, Inc, Amsterdam, the Netherlands) before and after treatment for 24 months in four groups, all images were digitally stored and analyzed using off-line post processing with QLAB Software, the average value of each measurement data was measured for six times.
| Follow-up
The clinical follow-up using standardized questionnaires and performed every 3 months during the 2 years follow-up period. The dosages and types of all other anti-hypertensive, anti-hyperlipidemia, and anti-arrhythmic drugs used during the follow-up were recorded for each patient. Seven-day Holter (BORSAM Co. Shenzhen, Guangdong Province, China) monitoring was performed at the baseline, 6 month, 12 month and at the end of the follow-up period.
Patients' diaries, cardiac function (NYHA classification), and adverse events during the follow-up period were collected every 3 months.
During the study, patients recorded diaries when they feel discomfort. Arrhythmia-related symptoms were self-evaluated or evaluated by 7-day Holter monitoring. The attending physicians recorded the blood pressure and ECG during each follow-up.
| Data collection
All the data will be entered and stored. To ensure high quality of the data, a double data entry method was used. A data monitoring committee, of which at least two members monitored the data management process regularly. All the data were frozen and then locked to prevent further editing after the validation by the data monitoring committee. All data are checked and handled correctly. 
| Statistical analysis
| RE SULTS
| Baseline characteristics
In the study, a total of 189 patients were enrolled and randomly divided into four groups, we compared their gender, age, BMI, past history, personal history, blood pressure, or other clinical characteristics and found no significant difference in baseline data between the study population (P > 0.05; Table 1 ).
| Routine blood test and biochemical examination results
We compared the routine blood test and blood biochemical examination results between the four groups patients before (M0) and after treatment for 24 months (M24 
| Echocardiography examination
The It seems to be that combination of ARB and statin may improve the cardiac remodeling.
| Sinus rhythm maintenance rate and incidence of permanent AF results
After 6 months' treatment, the sinus rhythm maintenance rate (SRMR) in groups B, C, and D was higher than that in group A, and the incidence of the progressing to permanent AF (IPPA) was lower than that in group A, but the difference was not statistically significant (P > 0.05). After 12 months follow-up, the SRMR in groups B, 
M12;
& P ＜ 0.05 after treatment data vs. corresponding value of group A. ★ P ＜ 0.05 after treatment data vs. corresponding value of group C 77.78%, 70.45%, and 79.17%, respectively. The line chart was shown that the trend of SRMR in the four groups during the followed up time of 24 months and the SRMR in group A was significantly reduced compared with other groups ( Figure 3A) . The incidence of permanent AF in each group was 31.71%, 11.11%, 14.29%, and 8.33%, respectively. The line chart was shown that the trend of IPPA in group A was significantly higher than other groups ( Figure 3B ).
With the duration of follow-up prolonged, the SRMR and the IPPA in M24 were significantly higher than in M6 and M12 in group A (all P < 0.01). At the end of the follow-up, the IPPA in groups B, C, and D was significantly lower than that in group A, the SRMR in group D was significantly higher than that in group C. The IPPA in group D was also significantly lower than that in group C (P < 0.05) ( Figure 3C,D) .
| D ISCUSS I ON
Atrial fibrillation is the most prevalent arrhythmia observed in clinical practice. Continued growth in AF-related morbidity and mortality raises the demand for therapies to prevent or delay AF onset and progression. 12 Paroxysmal AF often progresses to persistent or permanent AF, the transition from paroxysmal to persistent AF usually occurs via the change of an arrhythmogenic atrial substrate, with the characterized as structural remodeling processes consisting of atrial fibrosis, 13 atrial dilation, 14 and the altered of atrial cellular ultrastructure, 15, 16 which may lead to conduction disturbances that maintain AF. Intervening in this process often seen as the basis for upstream therapies that halt AF onset or delay its transition to more persistent forms. 12 The results of this study emphasized the role of upstream therapies in the prevention of AF in a Chinese hypertensive population and assist in the choice of an optimal therapy for such patients.
Hypertension is the most prevalent risk factor for new-onset AF.
However, few studies have addressed the effect of statins on the incidence of AF in patients with hypertension. Previous studies have
shown that statins can reduce the risk of AF in patients with sinus rhythm. 17, 18 Ma et al 19 demonstrated that statin treatment has been associated with a 19% decrease of AF risk in patients ≥65 years old.
These results provided some evidence for the potential benefit of statins beyond their lipid-lowering activity. 20 The possible mechanisms of statins to reduce the occurrence of AF are not exactly understood yet. There is growing evidence regarding the relationship between AF and inflammation. An et al 21 confirmed that early postoperative cardiac complications of coronary artery bypass graft surgery, such as AF, may be beneficially modulated by preoperative statins, involving their anti-inflammatory effects. Statins reduced the incidence of paroxysmal AF with a concomitant decrease in C-reactive protein levels, which are believed to be a risk factor for AF. 22 In addition, oxidative stress is involved in the pathogenesis of AF. 23, 24 The administration of statins was reported as an antioxidant agent in the prevention of AF. 25 Statins, which act as an antioxidant in addition to its lipid-lowering effects, reduced AF incidence. 26 Moreover, Statins prevented the development of AF by modulating extracellular remodeling. Statins modified extracellular components by regulating the expression of matrix metalloproteinases or their inhibitors. 27 Other potential mechanisms of action include alteration of membrane fluidity and ion channel conductance 28 and increased the number of endothelial progenitor cells. 29 In our study, the levels of hs-CRP in groups B and D patients in M24 were significantly lower than the values observed in patients before treatment (P < 0.01). This may be associated with the anti-inflammatory effects of statins. 
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